Corcept shares close at $80.46 ahead of third-quarter results
Key Facts
Corcept Therapeutics shares closed at $80.46 in the November 2, 2026 session, according to the company’s stock information page, which also recorded a high of $82.23 and a low of $79.40. The session came ahead of the company’s third-quarter results call, listed on its investor relations page for November 3 at 5:00 p.m. Eastern time. The call is expected to give the company an opportunity to present results for the fiscal period, while the press releases shown on its website did not include third-quarter results. Investors are therefore focused on what the company officially announces at the scheduled time. Earnings and revenue figures circulating in the initial version of the report could not be verified against an accessible reliable source.
Previously released second-quarter results provide context for the company’s performance ahead of the expected announcement. Revenue was $256.1 million in the second quarter of 2026, up 32% from the same period in 2025, according to the company’s statement. Net income was $43.0 million, compared with $35.1 million in the second quarter of the previous year. This year-over-year comparison puts revenue and net income in the background to the upcoming announcement, but it relates to the second quarter and does not represent third-quarter results. In its second-quarter earnings announcement, the company raised its 2026 revenue guidance to a range of $1.1 billion to $1.2 billion. Chief Executive Joseph Belanoff said the company expects “continued strength across our business,” adding that it had raised its annual revenue outlook.
Corcept, according to its description of its business, is a commercial-stage company developing drugs to treat serious endocrine, oncology, metabolic and central nervous system disorders by modulating the effects of the hormone cortisol. Its business spans multiple therapeutic areas, and the upcoming announcement will offer a chance to show what the latest period’s results add to the picture of its operations. One anticipated development in 2026 is the U.S. Food and Drug Administration’s decision on the relacorilant application for Cushing’s syndrome; the company said it expects a decision by December 17. It also said Lifyorli with nab-paclitaxel received FDA approval in March 2026 to treat platinum-resistant ovarian cancer, and the regimen was then listed as a preferred treatment in NCCN guidelines in April. These dates provide context for the company’s therapeutic pipeline, while the third-quarter results and November 3 call are the next milestones for shareholders.